NI201800005A - Anticuerpos específicos para tau hip - Google Patents
Anticuerpos específicos para tau hipInfo
- Publication number
- NI201800005A NI201800005A NI201800005A NI201800005A NI201800005A NI 201800005 A NI201800005 A NI 201800005A NI 201800005 A NI201800005 A NI 201800005A NI 201800005 A NI201800005 A NI 201800005A NI 201800005 A NI201800005 A NI 201800005A
- Authority
- NI
- Nicaragua
- Prior art keywords
- tau
- hip
- specific antibodies
- taupathies
- phf
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
Abstract
La presente invención se relaciona con una nueva clase de anticuerpo monoclonal que se une de forma específica al resto fosforilado de serina 396 en la tau patológica hiperfosforilada (PHF) (ps396), así como a métodos de uso de estas moléculas y sus fragmentos de unión tau en el tratamiento de la enfermedad de Alzheimer y de la taupatías.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1512211.2A GB201512211D0 (en) | 2015-07-13 | 2015-07-13 | Agents, uses and methods |
GBGB1518375.9A GB201518375D0 (en) | 2015-10-16 | 2015-10-16 | Agents,uses and methods |
Publications (1)
Publication Number | Publication Date |
---|---|
NI201800005A true NI201800005A (es) | 2018-10-19 |
Family
ID=56557664
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NI201800005A NI201800005A (es) | 2015-07-13 | 2018-01-11 | Anticuerpos específicos para tau hip |
Country Status (32)
Country | Link |
---|---|
US (4) | US10196439B2 (es) |
EP (1) | EP3322442A2 (es) |
JP (1) | JP6878395B2 (es) |
KR (1) | KR20180030047A (es) |
CN (1) | CN107847595B (es) |
AU (1) | AU2016292892B2 (es) |
BR (1) | BR112018000769A2 (es) |
CA (1) | CA2990555A1 (es) |
CL (1) | CL2018000096A1 (es) |
CO (1) | CO2017013318A2 (es) |
CR (1) | CR20180026A (es) |
DO (1) | DOP2018000012A (es) |
EA (1) | EA038703B1 (es) |
EC (1) | ECSP18002644A (es) |
GE (1) | GEP20227369B (es) |
HK (1) | HK1254357A1 (es) |
IL (1) | IL256791B (es) |
JO (1) | JO3711B1 (es) |
MA (1) | MA42446A (es) |
MX (1) | MX2018000505A (es) |
NI (1) | NI201800005A (es) |
NZ (1) | NZ738595A (es) |
PE (1) | PE20180607A1 (es) |
PH (1) | PH12018500062A1 (es) |
RU (1) | RU2727911C2 (es) |
SG (1) | SG10202101343RA (es) |
SV (1) | SV2018005611A (es) |
TN (1) | TN2017000541A1 (es) |
TW (1) | TWI741987B (es) |
UA (1) | UA123862C2 (es) |
WO (1) | WO2017009308A2 (es) |
ZA (1) | ZA201800070B (es) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA035943B1 (ru) | 2013-03-13 | 2020-09-03 | Протена Биосайенсес Лимитед | Антитело, связывающееся с тау-белком человека |
JO3627B1 (ar) | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
TWI827405B (zh) | 2015-06-05 | 2023-12-21 | 美商建南德克公司 | 抗-tau抗體及使用方法 |
AU2016289753C1 (en) | 2015-07-06 | 2021-08-05 | UCB Biopharma SRL | Tau-binding antibodies |
JO3711B1 (ar) | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
BR112018072389A2 (pt) | 2016-05-02 | 2019-02-19 | Prothena Biosciences Limited | anticorpos que reconhecem tau |
ES2933491T3 (es) | 2016-05-02 | 2023-02-09 | Prothena Biosciences Ltd | Inmunoterapia tau |
US10034861B2 (en) | 2016-07-04 | 2018-07-31 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
EP3484916B1 (en) * | 2016-07-12 | 2021-03-03 | H. Lundbeck A/S | Antibodies specific for hyperphosphorylated tau and methods of use thereof |
WO2018035137A1 (en) * | 2016-08-15 | 2018-02-22 | The Board Of Regents Of The University Of Texas System | Volume control device for manually operated resuscitator and ventilation apparatus and method of use |
BR112018013247A2 (pt) | 2016-10-28 | 2018-12-04 | H Lundbeck As | tratamentos de combinação compreendendo imidazopirazinonas para o tratamento de distúrbios psiquiátricos e/ou cognitivos |
KR20190077349A (ko) | 2016-10-28 | 2019-07-03 | 하. 룬드벡 아크티에셀스카브 | 이미다조피라지논의 투여를 포함하는 병용 치료 |
EP3551655A2 (en) | 2016-12-07 | 2019-10-16 | Genentech, Inc. | Anti-tau antibodies and methods of their use |
CN118165104A (zh) | 2016-12-07 | 2024-06-11 | 基因泰克公司 | 抗tau抗体和使用方法 |
CN110267985B (zh) * | 2017-01-04 | 2023-05-23 | H.隆德贝克有限公司 | 用于治疗眼科疾病的特异性针对过度磷酸化τ蛋白的抗体 |
EP3583123A1 (en) | 2017-02-17 | 2019-12-25 | Denali Therapeutics Inc. | Anti-tau antibodies and methods of use thereof |
JOP20180014A1 (ar) | 2017-02-27 | 2019-01-30 | Teijin Pharma Ltd | جسم مضاد متوافق مع البشر لعلاج أو الوقاية من الاضطرابات الإدراكية، وعملية لإنتاجه، وعامل لعلاج أو الوقاية من الاضطرابات الإدراكية باستخدامه |
EA039569B1 (ru) * | 2017-03-14 | 2022-02-11 | Х. Лундбекк А/С | Антитела, специфичные к гиперфосфорилированному тау-белку, и способы их применения |
IL270375B1 (en) | 2017-05-02 | 2024-08-01 | Prothena Biosciences Ltd | Antibodies that recognize tau |
MA50397A (fr) | 2017-10-16 | 2020-08-26 | Eisai R&D Man Co Ltd | Anticorps anti-tau et leurs utilisations |
AR113926A1 (es) | 2017-12-14 | 2020-07-01 | H Lundbeck As | Derivados de 1h-pirazolo[4,3-b]piridinas |
SI3723807T1 (sl) | 2017-12-14 | 2022-01-31 | H. Lundbeck A/S | Kombinirana zdravljenja, ki obsegajo dajanje 1H-pirazolo(4,3-b)piridinov |
WO2019121840A1 (en) | 2017-12-20 | 2019-06-27 | H. Lundbeck A/S | Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as pde1 inhibitors |
CN111655723A (zh) * | 2018-02-01 | 2020-09-11 | 扬森疫苗与预防公司 | 与tau特异性结合的结合分子 |
EP3935083A4 (en) | 2019-03-03 | 2022-11-30 | Prothena Biosciences Limited | ANTIBODIES RECOGNIZING TAU PROTEIN |
WO2020193500A1 (en) | 2019-03-28 | 2020-10-01 | H. Lundbeck A/S | Use of a ps396 assay to diagnose tauophaties |
EP4135841A1 (en) | 2020-04-15 | 2023-02-22 | Voyager Therapeutics, Inc. | Tau binding compounds |
JP2023528535A (ja) | 2020-06-25 | 2023-07-04 | メルク・シャープ・アンド・ドーム・エルエルシー | セリン413においてリン酸化されたタウを標的化する高親和性抗体 |
JP2023540796A (ja) | 2020-09-11 | 2023-09-26 | ヤンセン バイオテツク,インコーポレーテツド | ベータ鎖媒介性免疫を調節するための方法及び組成物 |
TW202227494A (zh) * | 2020-09-11 | 2022-07-16 | 美商健生生物科技公司 | 多特異性免疫靶向分子及其用途 |
WO2022104136A2 (en) * | 2020-11-12 | 2022-05-19 | Children's Medical Center Corporation | Methods and compositions for tauopathy diagnosis and treatment |
CN117043183A (zh) | 2020-12-16 | 2023-11-10 | 沃雅戈治疗公司 | Tau结合化合物 |
CN113702647B (zh) * | 2021-08-31 | 2024-03-15 | 普十生物科技(北京)有限公司 | 人生长分化因子15即时检测试剂盒、其制备方法及其应用 |
WO2023092004A1 (en) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
WO2023250388A1 (en) | 2022-06-22 | 2023-12-28 | Voyager Therapeutics, Inc. | Tau binding compounds |
WO2024059739A1 (en) | 2022-09-15 | 2024-03-21 | Voyager Therapeutics, Inc. | Tau binding compounds |
WO2024067401A1 (zh) * | 2022-09-26 | 2024-04-04 | 中美华世通生物医药科技(武汉)股份有限公司 | 包含Fc-高级脂肪酸链的超长效平台 |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
US4609546A (en) | 1982-06-24 | 1986-09-02 | Japan Chemical Research Co., Ltd. | Long-acting composition |
US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
US5101827A (en) | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
US4735210A (en) | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US4861581A (en) | 1986-12-05 | 1989-08-29 | Cancer Biologics, Inc. | Detection of necrotic malignant tissue and associated therapy |
US5750172A (en) | 1987-06-23 | 1998-05-12 | Pharming B.V. | Transgenic non human mammal milk |
US5648471A (en) | 1987-12-03 | 1997-07-15 | Centocor, Inc. | One vial method for labeling antibodies with Technetium-99m |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
CA2065299C (en) | 1989-08-09 | 2001-07-24 | Buck A. Rhodes | Direct radiolabeling of antibodies and other proteins with technetium or rhenium |
US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
WO1994025585A1 (en) | 1993-04-26 | 1994-11-10 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
ES2206447T3 (es) | 1991-06-14 | 2004-05-16 | Genentech, Inc. | Anticuerpo humanizado para heregulina. |
AU2235992A (en) | 1991-06-14 | 1993-01-12 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
WO1993001227A1 (en) | 1991-07-08 | 1993-01-21 | University Of Massachusetts At Amherst | Thermotropic liquid crystal segmented block copolymer |
ATE398176T1 (de) | 1991-12-06 | 2008-07-15 | Max Planck Gesellschaft | Phosphorylierungsepitope aus dem tau-protein zur diagnose und behandlung der alzheimer-krankheit |
EP0746609A4 (en) | 1991-12-17 | 1997-12-17 | Genpharm Int | NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES |
ES2146648T3 (es) | 1993-03-09 | 2000-08-16 | Genzyme Corp | Procedimiento de aislamiento de proteinas de la leche. |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
US6077835A (en) | 1994-03-23 | 2000-06-20 | Case Western Reserve University | Delivery of compacted nucleic acid to cells |
KR970029803A (ko) | 1995-11-03 | 1997-06-26 | 김광호 | 반도체 메모리장치의 프리차지 회로 |
MXPA01007895A (es) | 1999-02-03 | 2003-07-21 | Biosante Pharmaceuticals Inc | Particulas terapeuticas de fosfato de calcio, metodos de manufactura y usos. |
US6281005B1 (en) | 1999-05-14 | 2001-08-28 | Copernicus Therapeutics, Inc. | Automated nucleic acid compaction device |
NZ517372A (en) | 1999-07-29 | 2004-04-30 | Medarex Inc | Human monoclonal antibodies to HER2/neu |
NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
US20030162230A1 (en) * | 2000-09-27 | 2003-08-28 | Reagan Kevin J. | Method for quantifying phosphokinase activity on proteins |
PT1354034E (pt) | 2000-11-30 | 2008-02-28 | Medarex Inc | Roedores transgénicos transcromossómicos para produção de anticorpos humanos |
AU2002368077B2 (en) | 2001-07-12 | 2010-03-04 | Jefferson Foote | Super humanized antibodies |
US8003108B2 (en) * | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
EP1940442A4 (en) | 2005-08-04 | 2009-08-19 | Einstein Coll Med | PHOSPHORYLATION OF TAU BY ABL |
US10155816B2 (en) | 2005-11-28 | 2018-12-18 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
EP3255144A1 (en) | 2007-08-10 | 2017-12-13 | E. R. Squibb & Sons, L.L.C. | Recombineering construct for preparing transgenic mice capable of producing human immunoglobulin |
EP2185592B1 (en) | 2007-09-13 | 2013-01-23 | University Of Zurich Prorektorat Forschung | Monoclonal amyloid beta (abeta)-specific antibody and uses thereof |
US8609097B2 (en) | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
EP3329932A1 (en) | 2009-06-10 | 2018-06-06 | New York University | Immunological targeting of pathological tau proteins |
CA2778756A1 (en) | 2009-10-26 | 2011-05-05 | Otsuka Pharmaceutical Co., Ltd. | Benzazepine compound |
SG189136A1 (en) | 2010-10-07 | 2013-05-31 | Ac Immune Sa | Phosphospecific antibodies recognising tau |
DK2627672T3 (en) | 2010-10-11 | 2018-08-27 | Biogen Idec Int Neuroscience Gmbh | HUMAN ANTI-TAU ANTIBODIES |
PL2758433T3 (pl) * | 2011-09-19 | 2018-06-29 | Axon Neuroscience Se | Oparta na białku terapia i diagnozowanie patologii zależnej od Tau w chorobie Alzheimera |
BR122021017560B1 (pt) | 2011-10-07 | 2023-03-07 | Katholieke Universiteit Leuven | Anticorpo, polinucleotídeo, composição farmacêutica, usos de um anticorpo, método in vitro, método de detecção post-mortem de multimêros do fosfo-tau, método de detecção in vitro da formação de um complexo imunológico, kits de teste, linhagem celular isolada e método de detecção in vitro de multimêros de fosfo-tau |
BR112014024769A2 (pt) | 2012-04-05 | 2017-12-12 | Ac Immune Sa | anticorpo humanizado tau |
MX359555B (es) | 2012-07-03 | 2018-10-02 | Univ Washington | Anticuerpos para tau. |
AU2013302540B2 (en) | 2012-08-16 | 2018-02-15 | Ipierian, Inc. | Methods of treating a tauopathy |
EA035943B1 (ru) | 2013-03-13 | 2020-09-03 | Протена Биосайенсес Лимитед | Антитело, связывающееся с тау-белком человека |
US20160068818A1 (en) * | 2013-04-16 | 2016-03-10 | Glykos Finland Oy | A method for generating induced pluripotent stem cells |
WO2016007414A1 (en) | 2014-07-08 | 2016-01-14 | New York University | Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy |
JO3711B1 (ar) | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
EP3484916B1 (en) | 2016-07-12 | 2021-03-03 | H. Lundbeck A/S | Antibodies specific for hyperphosphorylated tau and methods of use thereof |
US10364286B2 (en) * | 2016-12-22 | 2019-07-30 | H. Lundbeck A/S | Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation |
CN110267985B (zh) | 2017-01-04 | 2023-05-23 | H.隆德贝克有限公司 | 用于治疗眼科疾病的特异性针对过度磷酸化τ蛋白的抗体 |
US10934438B2 (en) | 2017-04-27 | 2021-03-02 | Axalta Coating Systems Ip Co., Llc | Coatings and methods for using and producing the same |
-
2016
- 2016-06-29 JO JOP/2016/0135A patent/JO3711B1/ar active
- 2016-07-04 TW TW105121106A patent/TWI741987B/zh active
- 2016-07-12 PE PE2018000065A patent/PE20180607A1/es unknown
- 2016-07-12 US US15/207,836 patent/US10196439B2/en active Active
- 2016-07-12 TN TNP/2017/000541A patent/TN2017000541A1/en unknown
- 2016-07-12 MX MX2018000505A patent/MX2018000505A/es unknown
- 2016-07-12 BR BR112018000769-2A patent/BR112018000769A2/pt active Search and Examination
- 2016-07-12 RU RU2018100822A patent/RU2727911C2/ru active
- 2016-07-12 WO PCT/EP2016/066470 patent/WO2017009308A2/en active Application Filing
- 2016-07-12 UA UAA201800762A patent/UA123862C2/uk unknown
- 2016-07-12 KR KR1020187001209A patent/KR20180030047A/ko not_active Application Discontinuation
- 2016-07-12 CR CR20180026A patent/CR20180026A/es unknown
- 2016-07-12 NZ NZ738595A patent/NZ738595A/en unknown
- 2016-07-12 SG SG10202101343RA patent/SG10202101343RA/en unknown
- 2016-07-12 EA EA201890039A patent/EA038703B1/ru unknown
- 2016-07-12 IL IL256791A patent/IL256791B/en unknown
- 2016-07-12 AU AU2016292892A patent/AU2016292892B2/en active Active
- 2016-07-12 EP EP16745421.4A patent/EP3322442A2/en active Pending
- 2016-07-12 CA CA2990555A patent/CA2990555A1/en active Pending
- 2016-07-12 CN CN201680040472.7A patent/CN107847595B/zh active Active
- 2016-07-12 MA MA042446A patent/MA42446A/fr unknown
- 2016-07-12 JP JP2018501228A patent/JP6878395B2/ja active Active
- 2016-07-12 GE GEAP201614672A patent/GEP20227369B/en unknown
-
2017
- 2017-12-22 CO CONC2017/0013318A patent/CO2017013318A2/es unknown
-
2018
- 2018-01-04 ZA ZA2018/00070A patent/ZA201800070B/en unknown
- 2018-01-05 PH PH12018500062A patent/PH12018500062A1/en unknown
- 2018-01-11 SV SV2018005611A patent/SV2018005611A/es unknown
- 2018-01-11 NI NI201800005A patent/NI201800005A/es unknown
- 2018-01-11 DO DO2018000012A patent/DOP2018000012A/es unknown
- 2018-01-12 CL CL2018000096A patent/CL2018000096A1/es unknown
- 2018-01-12 EC ECIEPI20182644A patent/ECSP18002644A/es unknown
- 2018-10-19 HK HK18113433.8A patent/HK1254357A1/zh unknown
- 2018-11-13 US US16/188,489 patent/US10562962B2/en active Active
-
2019
- 2019-12-20 US US16/723,143 patent/US10934348B2/en active Active
-
2021
- 2021-01-08 US US17/144,355 patent/US11739140B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NI201800005A (es) | Anticuerpos específicos para tau hip | |
NI201900003A (es) | Anticuerpos específicos para la tau hiperfosforilada y sus métodos de uso | |
CO2017012974A2 (es) | Anticuerpos de unión a tau | |
ECSP18023386A (es) | Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas | |
EA201791050A1 (ru) | Конъюгаты антител и лекарственных средств | |
UY36889A (es) | Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas | |
CO2017012971A2 (es) | Anticuerpos de unión a tau | |
JO3576B1 (ar) | أجسام مضادة لـ tau واستخداماتها | |
CR20190193A (es) | Anticuerpos que se unen a la proteína de envoltura del virus zika y usos de los mismos | |
CL2017003311A1 (es) | Proteínas de fijación multiespecífica. | |
CO2018010286A2 (es) | Método para la purificación de proteínas | |
CR20190012A (es) | Anticuerpos específicos para la tauy hiperfosforilada y sus métodos de uso | |
AR105333A1 (es) | Anticuerpos específicos para tau hiperfosforilada y métodos de uso de los mismos | |
AR109258A1 (es) | Anticuerpos específicos para la tau hiperfosforilada y sus métodos de uso | |
EA201892570A1 (ru) | Антитела, специфичные к гиперфосфорилированному тау-белку, и способы их применения |